Memorial Sloan Kettering Reports Breakthroughs in Stem Cell Memory, Cancer DNA Mapping, and Immune Evasion

Memorial Sloan Kettering’s March 2026 report reveals breakthroughs in skin stem cell memory, a 48,000-patient DNA map, and how BAF helps cancer hide.

By: AXL Media

Published: Mar 28, 2026, 11:08 AM EDT

Source: Information for this report was sourced from Memorial Sloan Kettering Cancer Center

The Long-Lasting Epigenetic Legacy of Inflammation

Skin stem cells, the primary engines of tissue regeneration, have been found to harbor a sophisticated form of molecular memory that persists for over a year. A collaborative study between MSK and Rockefeller University utilized AI modeling to prove that past inflammation leaves certain DNA regions, known as long-term memory domains, permanently accessible. This structural change allows cells to react more efficiently to future injuries but may also contribute to the long-term tissue dysfunction associated with aging. By deciphering the mathematical instructions within the genome, researchers can now predict which cells will retain these heritable changes, offering a new window into how repeated stress shapes disease susceptibility over time.

Mapping the Genomic Complexity of 450 Cancer Types

In one of the most comprehensive genetic studies to date, MSK researchers analyzed the DNA of more than 48,000 patients using the MSK-IMPACT® sequencing tool. The data, published in Cancer Cell, reveals a critical nuance in personalized oncology: the same genetic mutation can have vastly different impacts depending on the cancer type. While a mutation might be a primary driver in common cancers, it often plays a secondary or late-stage role when found in unexpected tumor types. This detailed map suggests that a one-size-fits-all approach to mutation-targeted therapy is insufficient and that a more refined classification system is necessary to accurately match patients with the most effective treatments.

How BAF Shields Unstable Cells from Immune Attack

Chromosomal instability is a hallmark of many aggressive cancers, often leading to the formation of "micronuclei" that should naturally trigger an immune response. However, a new study from the Sloan Kettering Institute identifies a protein called BAF as a key protector that helps cancer cells hide this abnormality. BAF works by recruiting an enzyme to break down errant DNA before the immune-sensing protein cGAS can detect it. By removing BAF in laboratory settings, researchers were able to "unmask" the cancer cells, triggering a robust immune attack. This suggests that BAF represents a significant therapeutic vulnerability that could be exploited to make "invisible" tumors visible to the body’s natural defenses.